Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)
July 10, 2020
Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI
June 18, 2019
Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer
February 14, 2019
Atox Bio Announces Independent Safety Monitoring Committee Recommendation To Continue Phase 3 Study Of Reltecimod In Necrotizing Soft Tissue Infections
September 25, 2018
Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)
May 29, 2018
Atox Bio Awarded Next Milestone – based Option by BARDA to Support Continued Development of Reltecimod for Necrotizing Soft Tissue Infections
September 25, 2017
Atox Bio’s Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned
May 23, 2017
Atox Bio Announces Independent Safety Monitoring Committee Recommendation To Continue Phase 3 Study Of Reltecimod In Necrotizing Soft Tissue Infections
November 3, 2016
Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of Reltecimod for Necrotizing Soft Tissue Infections
June 15, 2016
Appetite suppressor? Atox flesh-eating bug phase III dials down immune reply
December 8, 2015
Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)
December 7, 2015
Atox Bio Announces Appointment of Biotech Veteran Daniel D. Burgess as Chairman of the Board
December 15, 2014
Atox Bio Awarded Contract worth up to $24 Million for the Development of Reltecimod by the Biomedical Advanced Research and Development Authority (BARDA)
September 29, 2014
Reltecimod granted orphan medicinal product designation in the European Union for the treatment of necrotizing soft tissue infections (NSTI)
August 4, 2014
Atox Bio Publishes Data Demonstrating the Broad Therapeutic Effect of its Flagship Product in Treating “Flesh Eating Bacteria”
April 10, 2013
Atox Bio Announces Positive Top Line Results in the Reltecimod Necrotizing Soft Tissue Infections (NSTI) Phase 2a Trial
November 20, 2012
FDA grants Fast Track designation to Atox Bio’s Reltecimod for the treatment of necrotizing soft tissue infections (NSTI)
September 10, 2012
Atox Bio Raises $3.25 million to Advance Development of Reltecimod, a Novel Therapy for the Treatment of Severe Bacterial Infections, Currently in Phase 2 Clinical Trials
December 20, 2011
Atox Bio granted orphan drug designation for Reltecimod for the treatment of necrotizing soft tissue infections (NSTI)
October 25, 2011
End of Phase 1-Atox Bio announces successful completion of phase 1 for Reltecimod, a novel immunomodulator being developed for severe bacterial infections and sepsis
May 12, 2011
Atox Bio raises $2.1 Million to advance development of Reltecimod, a novel therapy for the treatment of severe bacterial infections
October 14, 2010